In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the company on March 13 at a price of $510 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- MaxCyte price target lowered to $6 from $8 at BTIG
- Vertex Pharmaceuticals announces MHRA approval of ALYFTREK for CF
- Vertex non-opioid pain drug picked up by UnitedHealth
- Vertex Pharmaceuticals: Buy Rating Driven by Outpatient Market Potential and Strategic Initiatives for Journavx
- Goldman Sachs starts Sionna Therapeutics with Early-Stage Biotech designation